The FDA has approved a new combination treatment—niraparib plus abiraterone acetate (Akeega) taken with low‑dose prednisone—for adults with metastatic castration‑sensitive prostate cancer (mCSPC) whose tumors have a harmful BRCA2 gene change, confirmed by a specialized test. This means some men with a BRCA2‑positive cancer now have a targeted option added to standard hormone‑...
Want to know the latest news and articles posted on CancerConnect?
Then subscribe to their feed now! You can receive their updates by email, via mobile or on your personal news page on this website.
See what they recently published below.
Website title: CancerConnect - By combining information with a social community CancerConnect provides cancer patients and their caregivers a unique destination to seek information, support, and inspiration.
